Morisaki Hiroko, Nakanishi Norifumi, Kyotani Shingo, Takashima Atsushi, Tomoike Hitonobu, Morisaki Takayuki
Department of Bioscience, Osaka University Graduate School of Pharmaceutical Sciences, Suita, Osaka, Japan.
Hum Mutat. 2004 Jun;23(6):632. doi: 10.1002/humu.9251.
Primary pulmonary hypertension (PPH) is a potentially lethal disorder, in which heterozygous mutations within the bone morphogenetic protein type II receptor (BMPR2) gene (BMPR2) have been identified. We conducted a molecular study of BMPR2 mutations in 4 Japanese families with familial PPH and 30 Japanese patients with sporadic PPH, and found 13 different mutations, of which 10 were novel, including missense (n=2), nonsense (n=4), frameshift (n=3), and splice-donor site (n=1) mutations. In total, BMPR2 mutations were found in all 4 familial PPH cases and 12 (40%) of the sporadic PPH cases. Further, a majority of the mutations found were predicted to cause premature termination, as previously reported. In the 9 mutations found in the sporadic cases, 2 were shown to be de novo, 2 were shared in multiple cases, 1 was shared with an FPPH case, and 1 was the same as previously reported in Caucasian FPPH. These results indicate that a substantial portion of Japanese PPH patients carry BMPR2 mutations with considerable heterogeneity.
原发性肺动脉高压(PPH)是一种潜在的致命性疾病,其中已鉴定出骨形态发生蛋白II型受体(BMPR2)基因(BMPR2)内的杂合突变。我们对4个日本家族性PPH家庭和30例日本散发性PPH患者进行了BMPR2突变的分子研究,发现了13种不同的突变,其中10种是新的,包括错义突变(n = 2)、无义突变(n = 4)、移码突变(n = 3)和剪接供体位点突变(n = 1)。总共在所有4例家族性PPH病例和12例(40%)散发性PPH病例中发现了BMPR2突变。此外,如先前报道,发现的大多数突变预计会导致提前终止。在散发性病例中发现的9种突变中,2种显示为新发突变,2种在多个病例中共享,1种与家族性PPH病例共享,1种与先前在白种人家族性PPH中报道的相同。这些结果表明,相当一部分日本PPH患者携带具有相当大异质性的BMPR2突变。